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Vibrio vulnificus is a pathogenic bacterium causing primary
septicemia, which follows a classical septic shock pathway,
including an overwhelming inflammatory cytokine response. In
this study, we identified a putative lipoprotein of V. vulnificus,
encoded by the ilpA gene, as one of the surface proteins that
specifically reacted with the antibodies raised against outer
membrane proteins of V. vulnificus. Using a mutant V. vulni-
ficus in which its ilpA gene was knocked out, we found that
IlpA is important in the production of interferon- in human
peripheral blood mononuclear cells. Production of tumor
necrosis factor- and interleukin-6 is also induced by the
recombinant IlpA (rIlpA) in human monocytes. Lipidation of
the rIlpA was observed by in vivo labeling in Escherichia coli.
Experiments using the mutant IlpA, which is unable to be
modified by lipidation, indicate that the lipid moiety of this
protein has an essential property for cytokine production in
human cells. Pretreatment of monocytes with antibodies
against Toll-like receptor 2 (TLR2) inhibited production of both
tumor necrosis factor- and interleukin-6. The role of TLR2 in
IlpA-induced cytokine production was confirmed by an in vitro
assay, in which only the TLR2-expressing cells showed a dramatic
induction of nuclear factor-B activity by rIlpA. In addition, rIlpA
treatment resulted in induction of TLR2 transcription in human
cells. In comparison with the wild type V. vulnificus, the ilpA
mutant showed a reducedmortality inmice. These results demon-
strate that IlpA of V. vulnificus functions as an immunostimulant
to human cells via TLR2.
Vibrio vulnificus, a Gram-negative bacterium found com-
monly in the estuarine environment, has been frequently asso-
ciated with primary septicemia following the consumption of
contaminated shellfish. Over 50% of the primary septicemia
patients caused by V. vulnificus died of multiorgan failure as a
result of a rapidly progressive shock syndrome (1, 2).
Extracellular substances produced by V. vulnificus, such as
hemolytic cytolysin (3, 4) and elastase (5), had been exten-
sively studied as candidate virulence factors responsible for
its pathogenesis. Surface structures such as lipopolysaccha-
ride (LPS)2 (6, 7) and outer membrane proteins (8, 9) were
also studied as candidates for V. vulnificus virulence factors.
Based on the attenuated mouse lethality by a noncapsulated
mutant V. vulnificus, capsular polysaccharide was also
proven to be important in the pathogenesis of V. vulnificus
(10). Type IV pilin was confirmed to be involved in the vir-
ulence of V. vulnificus via genetic deletion of the pilD or pilA
genes (11, 12). In addition, motility was discovered as a vir-
ulence determinant of V. vulnificus (13, 14).
One of the distinct characteristics in V. vulnificus pathology
is a rapidly progressing septic shock syndrome (15, 16). Septic
shock usually results from the overproduction and dysregula-
tion of host cytokines in response to invading microorganisms.
Inflammation-associated cytokines, such as tumor necrosis fac-
tor- (TNF-), interferon- (IFN-), interleukin-1 (IL-1), and
IL-6, play pivotal roles in the host immune response to infection
(17, 18). A variety of bacterial products, including LPS, capsular
polysaccharide, peptidoglycan, lipoarabinomannans, and por-
ins, has been identified to elicit or modulate the release of cyto-
kines fromhost cells in both in vivo and in vitromodels (19). For
example, initial interaction of Neisseria gonorrhoeae with
mucosal epithelial cells triggers the release of inflammatory
cytokines, including IL-6 and IL-8, which subsequently recruit
and activate other immune cells at the site of infection (20, 21).
Therefore, the involvement of V. vulnificus surface molecu-
les(s) in its interaction with host cells can be postulated, which
may be recognized by immune cells and thus trigger cytokine
production. The interaction between the surface molecules of
V. vulnificus and the immune cells may occur by specific recog-
nition via the receptors on the immune cells. A variety of host
cell receptors has been implicated in the recognition of bacteria
or their components. One of them is the Toll-like receptor
(TLR) family, which plays a central role in innate immune
defenses (22, 23). The human TLR family is categorized into at* Thisworkwas supportedby the21stCentury FrontierMicrobialGenomics and
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least 10 distinct receptors, which convey information in
response to differentmicrobial components resulting in activa-
tion of nuclear factor-B (NF-B), the transcription factor
involved in the expression of proinflammatory cytokines, che-
mokines, and adhesion molecules (24). The ligands recognized
by each TLR have the conservedmolecular patterns shared by a
broad range of pathogens. For instance, TLR4 is a principal
signal transducer in the recognition of LPS (25, 26). TLR2 con-
fers responsiveness to various bacterial compounds, such as
bacterial lipoprotein (27), lipoarabinomannan (28), lipotei-
choic acid (29), and peptidoglycan (30).
In this study, we isolated an outer membrane protein of V.
vulnificus, which is highly immunoreactive, and identified it as
a lipoprotein. The lipidated form of this protein stimulates the
production of proinflammatory cytokines in human mono-
cytes. In vitro assays further indicate that TLR2 is required for
recognition of this V. vulnificus lipoprotein.
EXPERIMENTAL PROCEDURES
Cultivation of Bacteria—The strains and plasmids used in
this study are listed in Table 1. Escherichia coliDH5 and BL21
(DE3) were grown in Luria-Bertani (LB) (1% (w/v) tryptone,
0.5% (w/v) yeast extract, 1% (w/v) NaCl, pH 7.5) supplemented
with the appropriate antibiotics at 37 °C. Various strains of V.
vulnificus, ATCC29307 (wild type), ilpA knock-out mutant,
and ilpA mutant carrying pLAFRilpA were cultured in LBS
broth (1% (w/v) tryptone, 0.5% (w/v) yeast extract, 2% (w/v)
NaCl, pH7.5) at 30 °Cwith tetracycline (2g/ml)whenneeded.
Immunoscreening of the V. vulnificus Expression Library—
Outer membrane proteins (OMPs) were prepared from V.
vulnificusATCC29307 and used for intravenous immunization
of a rabbit as described (14). The resultant polyclonal antibod-
ies specific to OMPs were used for the immunoscreening
experiment. The V. vulnificus expression library was con-
structed by cloning genomic DNA partially digested with
Sau3AI into a ZAPII vector (Stratagene). Recombinant
phage DNA was packaged in vitro using Gigapack Gold as
described by the manufacturer (Stratagene). The amplified
library (with a titer of 9  106 plaque-forming units/ml) was
screened primarily using a 1:2,000 dilution of rabbit antibodies
raised against V. vulnificus OMPs. Plaques distinct from the
background level of antibody binding to the filter were further
purified by the second and third screenings. Homogeneous
plaques expressing the surface antigens were selected and
excised to a pBK-CMV phagemid, as instructed by the manu-
facturer (Stratagene). The identities of the phagemid inserts
were verified by automatic sequencing of the double-stranded
plasmids.
Construction of the ilpAKnock-outMutant V. vulnificus—An
840-bp region upstream of the ilpA open reading frame (ORF)
was amplified from the genomic DNA of V. vulnificus ATCC
29307 using the following two primers: ilpA-upF (5-GTC-
TABLE 1
Cell lines, bacterial strains, and plasmids used in this study
The abbreviations used are as follows: Ap, ampicillin; Cm, chloramphenicol; Km, kanamycin; Tc, tetracycline; r, resistant.
Strain/plasmid Genotype/source Ref.
Human cell lines
HEK-293 Hypotriploid human cell line, organ; kidney ATCC
293-hTLR2/CD14 HEK 293 cells transfected with the plasmids expressing human TLR2 and
human CD14
InvivoGen
293-hTLR4/MD2-CD14 HEK 293 cells transfected with the plasmids expressing human TLR4 and
human MD2/CD14
InvivoGen
Bacterial strains
E. coli
DH5 supE44 lacU169 (80 lacZ M15) hsdR17 recA1 endA1 gyrA96 thi-1 relA1 Invitrogen
BL21 (DE3) E. coli strain B F dcm ompT hsdS (rBmB) gal (DE3) Invitrogen
SM10pir thi thr leu tonA lacy supE recA::RP4-2-Tc::Mupir, oriT of RP4,
conjugational donor; Kmr
61
XLOLR (mcrA)183 (mcrCB-hsdSMR-mrr) 173 endA1 thi-1 recA1 gyrA96 relA1
lacF proAB lacIqZM15 Tn10 (Tetr) Su 
V. vulnificus
ATCC29307 Clinical isolate ATCC
YS101 ilpAmutant of ATCC29307 This study
Plasmids
pLAFR5 RP4, derivative of pLAFR3 containing a double cos cassette; Tcr 32
pLAFR-ilpA pLAFR5 with 2,135-bp V. vulnificus ilpA; Tcr This study
pBK-CMV Phagemid derived from ZAP II Stratagene
pEX3 pBK-CMV, ilpA This study
pBluescript SKII() Cloning vector; ori, oriF1, lacZ; Apr Stratagene
pYS1 pBluescript II SK() with 840-bp upstream region of ilpA; Apr This study
pYS2 pYS1 with 1,010-bp downstream region of ilpA; Apr This study
pDM4 Suicide vector; oriR6K; Cmr 31
pYS3 pDM4 containing SacI and KpnI fragment of pYS2; Cmr This study
pET28b Expression vector; T7 lac promoter, oriF1; Kmr Novagen
pETilpA pET28 containing 810-bp complete ilpA coding region; Kmr This study
pETmilpA pET28 containing 741-bp incomplete ilpA coding region; Kmr This study
pFLAG-CMV N-terminal FLAG expression vector derived from the pCMV5 transient
expression vector; CMV promoter, oriSV40; Apr
Sigma
pFLAG-TLR2 pFLAG-CMV containing 2.3-kb human TLR2 coding region; Apr 35
pFLAG-TLR4 pFLAG-CMV containing 2.4-kb human TLR4 coding region; Apr 35
p(IL6B)350hu.IL6P-luc luciferase reporter vector fusing to NF-B enhancer; ori, oriF1; Apr 36
pCH110 Monitoring and normalizing expression vector in eukaryotic cells;
oripBR322, oriSV40, lacZ; Apr
GE Healthcare
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CGAGCTCGGCGGAGTGAAGTTTGGC-3; the underlined
sequence denotes a SacI restriction site) and ilpA-upR (5-GCG-
AGGATCCAGTAAATCTCCTTATTATTTTGAC-3; the
underlined sequence indicates a BamHI restriction site). The
PCR product was then cloned into pBluescript SKII () to pro-
duce pYS1. A DNA fragment containing 1,010 bp downstream
of the ilpA ORF was generated using the primers, ilpA-downF
(5-GGACGGATCCCAAAGGCGGCGTAGTAAAAG-3; the
underlined sequence denotes a BamHI restriction site) and
ilpA-downR (5-CTGGGGTACCGATTGGGCACTTCTCA-
GCG-3; the underlined sequence represents a KpnI restriction
site). The DNA fragment was cloned into the corresponding
sites of pSY1 resulting in pYS2. An approximate 1.85-kb DNA
fragment from pYS2, digested with SacI and KpnI, was ligated
with a suicide vector pDM4 (31) to generate pYS3. An E. coli
SM10 pir strain carrying pYS3 was conjugated with V. vulni-
ficus ATCC29307, and the exconjugants were then selected on
a thiosulfate citrate bile sucrose medium supplemented with
chloramphenicol. Colonies with characteristics indicating a
double homologous recombination event (resistance to 5%
sucrose, and sensitivity to chloramphenicol) were further con-
firmed by PCR using primers ilpA-upF and ilpA-downR, and
finally given the name YS101.
Complementation of ilpA Mutant with the Intact ilpA
Gene—An intact ilpA gene was amplified from the genomic
DNA of wild type V. vulnificus ATCC29307 by PCR using the
following primer set: ilpA-comF (5-GGTTGGATCCATTG-
GTGAGCT-3; the underlined sequence denotes a BamHI
restriction site) and ilpA-comR (5-TATCAAGCTTCTCTT-
GGGATCATTTGAAA-3; the underlined sequence indicates
a HindIII restriction site). The amplified ilpADNA fragment of
1,159 bp was digested with BamHI and HindIII, and then
cloned into a broad range host plasmid, pLAFR5 (32), resulting
in the positioning of ilpAORF downstream of the lac promoter
in pLAFR5. The resultant plasmid, pLAFRilpA, in E. coli SM10
pir was transferred into the ilpAmutant (YS101) by conjuga-
tion, and the exconjugants were selected on thiosulfate citrate
bile sucrose agar containing tetracycline (2 g/ml).
Expression and Purification of Recombinant IlpA Proteins—
Two oligonucleotides, lipo-F (5-CATGCCATGGCTATGAA-
ATTTAGCCTTAAAGG-3; the underlined sequence denotes
an NcoI restriction site) and lipo-R (5-CCCAAGCTTCCAG-
CCTTTTACTACGCC-3; the underlined sequence represents
a HindIII restriction site), were used to amplify an 810-bpDNA
fragment containing the complete ORF of the ilpA gene from
the genomic DNA of V. vulnificus. NcoI and HindIII sites
located at both ends of the resultant ilpA DNA were used to
clone this DNA into the pET28b expression plasmid (Novagen)
to generate the plasmid pETilpA.The recombinant IlpA (rIlpA)
protein was overexpressed in E. coli BL21(DE3) carrying
pETilpA by adding isopropyl thio--D-galactoside (IPTG;
Sigma) at a concentration of 1 mM, and purified using a Ni2-
nitrilotriacetic acid affinity column as directed by themanufac-
turer (Qiagen).
Using primers, mlipo-F (5- CATGCCATGGATGGGC-
GAAAAAGCGACTGAC-3; the underlined sequence denotes
an NcoI restriction site) and lipoR, we prepared the truncated
ilpA gene, which lacked the 5-end of DNA fragment (69 bp)
containing the consensus sequence for lipidation. The resultant
ilpA DNA fragment of 741 bp was then used to clone into
pET28b as described above. The truncated rIlpA protein was
overexpressed in E. coli BL21 (DE3) carrying the resultant plas-
mid, pETmilpA, and purified in the same manner as the intact
rIlpA protein.
Determination of the Recombinant IlpA Protein Lipidation—
In vivo labeling of rIlpA protein with [3H]palmitic acid was
performed as described (33). Briefly, various E. coli strains,
DH5 carrying pET28b, DH5 carrying pETilpA, BL21 (DE3)
carrying pET28b, and BL21 (DE3) carrying pETilpA, were
grown to the mid-log phase (A600	 0.6–0.8), and the incuba-
tion was continued for 12 h in the presence of 50 Ci of
[3H]palmitic acid (Amersham Biosciences) without or with
IPTG. After the labeling was stopped by adding 10% trichloro-
acetic acid (w/v), the labeled bacterial cells were resuspended
in boiling buffer (2% (w/v) SDS, 50 mM Tris-Cl, pH 8.0),
boiled for 10 min, and then broken by sonication. The bac-
terial extracts were then phase-partitioned into aqueous and
detergent phases with the addition of 5% Triton X-114 at
37 °C. The pellet fraction was washed three times with radio-
immunoprecipitation buffer (1% (v/v) Nonidet P-40, 0.5%
(w/v) deoxycholic acid, 0.1% (w/v) SDS, 50 mM Tris-Cl, pH
8.0) before being resuspended in sample buffer for SDS-
PAGE. An equal microgram of each fraction was subjected to
10% (w/v) SDS-PAGE and transferred to a polyvinylidene
difluoride membrane. The membrane was treated with
Amplify solution (Amersham Biosciences) and exposed to
preflashed Hyperfilm-MP (Amersham Biosciences) for 2
weeks at 70 °C.
Western Blot Analysis—Purified rIlpA (100 g) was mixed
with 0.5ml of complete Freund’s adjuvant (Sigma), and injected
intraperitoneally into a specific pathogen-free rat (CrjBgi:
CD[S.D.]IGS, 7-week-old, female). Two additional immuniza-
tions were performed with the same amount of rIlpA protein
mixed with incomplete Freund’s adjuvant (Sigma) at 2 and 4
weeks after the primary immunization. A week after the third
immunization, serum was obtained from the immunized rat
and used for Western blot analysis.
Lysates of various V. vulnificus, wild type ATCC29307,
YS101, and YS101 harboring pLAFRilpA, were prepared in a
lysis buffer (50mMTris-HCl, pH 6.8, 100mM dithiothreitol, 2%
(w/v) SDS, 0.1% (w/v) bromphenol blue, and 20% (v/v) glyc-
erol), separated in a 10% (w/v) SDS-PAGE, and transferred to a
nitrocellulose membrane (Millipore). The membranes were
incubated with IlpA antisera (1:20,000) in a blocking solution
(PBS with 5% (w/v) skim milk and 0.05% (v/v) Tween 20),
washed three times with PBS containing 0.1% (v/v) Tween 20,
and incubated with alkaline phosphatase-conjugated anti-rat
immunoglobulin G. The immunoreactive bands were visual-
ized by using nitro blue tetrazolium and 5-bromo-4-chloro-3-
indolyl phosphate system (Promega).
Preparation of Human Peripheral Mononuclear Cells and
Monocytes—Human peripheral mononuclear cells (PBMCs)
were prepared by density gradient centrifugation using Ficoll
(Amersham Biosciences) and resuspended in RPMI 1640
medium supplemented with 10% heat-inactivated fetal bovine
serum, 100 units/ml penicillin, 100 g/ml streptomycin, and 2
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mML-glutamine. Prepared PBMCs (1 105 cells) were cultured
in 96-well plates. Monocytes (
95%) were isolated by counter-
current elutriation from peripheral blood as described previ-
ously (34). Certain numbers of monocytes, 1 105 or 5 105,
were cultivated in 96-well or 24-well flat-bottom microtiter
plates, respectively. Cells were cultured with or without V.
vulnificus lysates, the rIlpA protein, concanavalin A, or LPS.
Measurement of Cytokines—PBMCs and monocytes in
96-well plates (1  105 cells per well) were coincubated with
culture medium, bacterial lysates, or rIlpA protein at the indi-
cated concentration for 18 h. For comparison, cells were also
treated with commercially available E. coli LPS (Sigma). Cell-
free supernatants were then collected by centrifugation, trans-
ferred to new tubes, and stored at 70 °C until analysis. The
levels of each cytokine in the supernatants were determined
using enzyme-linked immunosorbent assays (BD Biosciences).
Concentration of each cytokine was determined based on the
standard curve of the corresponding cytokine, which had been
purified and was available commercially (IFN- from BD Bio-
sciences; TNF- and IL-6 from BIOSOURCE).
Blocking Experiments with Polymyxin B or with Anti-TLR2
Antibodies—Monocytes were preincubated for 1 h with
medium containing 10 g/ml human TLR2 monoclonal anti-
bodies (BioLegend) or its isotype control IgG (BioLegend). To
examine the role of residual LPS in the prepared rIlpA protein
fraction on cytokine production by monocytes, polymyxin B
(Sigma) was added to the rIlpA at a concentration of 20 g/ml
prior to being incubated with the prepared monocytes.
Transfection and Luciferase Assay—Using Lipofectamine
(Invitrogen), human embryonic kidney 293 (HEK 293) cells
(5  105) were transfected with 1.0
g of pFLAG-TLR2 (35), 1.0 g of
p(IL6B)350hu.IL6P-luc (36), and
0.5 g of pCH110 (GE Healthcare)
in 24-well plates. As a control, the
plasmid pFLAG-CMV (Invitrogen)
was transfected instead of pFLAG-
TLR2. pFLAG-TLR4 (35) was used
to transfect HEK 293 cells along
with p(IL6B)350hu.IL6P-luc and
pCH110. After 24 h, the transfected
cells were stimulated with either
rIlpA or LPS. After an additional
20-h incubation, the cells were lysed
and assayed for luciferase activity
using a luciferase reporter assay
system (Promega). Normalized re-
porter activity is expressed as the
luciferase activities derived from
p(IL6B)350hu.IL6P-luc divided
by the activities of -galactosidase
derived from pCH110 of the same
transfected cells.
RT-PCR of TLR mRNAs—Using
TRIzol reagent (Invitrogen), total
RNAs were isolated from human
PBMCs (2  106) stimulated with
either rIlpA or E. coli LPS (Sigma)
at the concentration of 1.0 g/ml. As a control, total RNA
was also prepared from the same number of PBMCs. In addi-
tion, HEK293-hTLR2/CD14 (indicated as 293-hTLR2) and
HEK293-hTLR4/MD2-CD14 (indicated as 293-hTLR4) cell
lines (Table 1) were treated with either rIlpA or LPS and
subjected to RNA preparation.
Two micrograms of each RNA were converted into cDNA
using the oligo(dT) primer via the action of reverse tran-
scriptase, which was then amplified for 22 cycles using specific
sets of primers. Two primers for TLR2, TLR2-F (5-GCCAAA-
GCTTTGATTGATTGG-3) and TLR2-R (5-TTGAAGTTC-
TCCAGCTCCTG-3), were designed on the nucleotide
sequences of human TLR2 (GenBankTM accession number
NM003264), whereas TLR4-specific primers, TLR4-F (5-
TGCGGGTTCTACATCAAA-3) and TLR4-R (5-CCATCC-
GAAATTATAAGAAAAGTC-3), were made based on the
nucleotide sequence of human TLR4 (GenBankTM accession
number U88880). Two oligonucleotides derived from the
GAPDH sequence (5-GGTCATCCCTGAGCTGAACG-3
and 5-TCCGTTGTCATACCAGGAAAT-3) were used to
amplify the control RNA. Each cycle of the PCR consisted of a
denaturation step (94 °C, 30 s), an annealing step (52 °C, 30 s),
and an elongation step (72 °C, 30 s). The PCR products were
subjected to electrophoresis in a 1.8% agarose gel.
LD50 Determination—For determination of LD50 , specific
pathogen-free, 7-week-old, female ICRmice were used without
pretreatment with iron dextran. Cultures of bacterial strains
grown overnight in LBS medium were freshly cultivated in the
same medium up to an A600 of 0.7, harvested, washed once in
PBS, and then resuspended in PBS. One hundredmicroliters of
FIGURE 1.Genetic organization of the insert DNA in plasmid pEX3, and identification of the gene encod-
ing the protein that reacted with anti-OMPvv antibodies. A, pEX3 is one of the immunoreactive clones,
which was isolated by immunoscreening of the V. vulnificus expression library with the antibodies raised
against OMPs of V. vulnificus (OMPvv). A 3.66-kb DNA fragment of pEX3 contains four complete ORFs that
encodeanABCpermease, a lipoprotein, ahypothetical protein, a SecY-interactingprotein, andapartialORF for
a hypothetical protein. Sizes of the putative proteins are indicated in parentheses. Primers used for the con-
struction and confirmation of ailpAmutant V. vulnificus are denotedwith arrows. B, 20g of protein extracts
from E. coli XLOLR and E. coli XLOLR carrying pEX3was subjected toWestern analysis using antibodies against
OMPvv. An30-kDa protein appeared as an immunoreactive band and is indicated by an arrow. Lane 1, lysate
prepared from XLOLR; and lane 2, lysate prepared from XLOLR carrying pEX3.
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serial dilutions of the bacterial suspension were then injected
intraperitoneally into sixmice per dilution group. The numbers
of dead mice were determined 24 h after the injection, and the
LD50 value was calculated using the equation described previ-
ously by Reed and Muench (37).
Nucleotide Sequence Accession Number—The nucleotide
sequences of the ilpA gene isolated from V. vulnificus
ATCC29307 were deposited in the GenBankTM data base
under the accession number of DQ177330.
Statistical Analysis—Data are presented as means  S.D.
derived from at least three independent experiments. Student’s
t test (SYSTAT program, SigmaPlot version 9; Systat Software
Inc.) was used to evaluate the statistical significance of the
results.
RESULTS
Isolation of the Immunoreactive Clone from Immunoscreen-
ing V. vulnificus OMPs—Approximately 30,000 plaques from
the ZAPII-based expression library of V. vulnificus were
screened to isolate the clones expressing the proteins reacting
with the antibodies against V. vulnificus OMPs. Twelve candi-
date plaques showing reproducible immune response with
anti-OMP serum were isolated, and the insert DNAs in the
isolated phages were excised to pBK-CMV phagemids. Among
the 12 isolated clones, 3 of them, pEX3, pEX19, and pEX21, had
an identical 3.66-kb DNA fragment (Fig. 1A). The DNA insert
of pEX3was found to contain four completeORFs coding for an
ABC permease, a putative lipoprotein, a hypothetical protein, a
SecY-interacting protein (Syd), and a partial ORF encoding
another hypothetical protein.
To examine which gene product was responsible for the
immune reaction with anti-OMP serum, the lysate of E. coli
XLOLR containing pEX3 was subjected to aWestern blot anal-
ysis using anti-OMP serum (Fig. 1B). As a control, lysates of
E. coliXLOLRwithout any plasmid were reacted with the same
serum. A strong immunoreactive band of 30 kDa was
detected only in the lysate of XLOLRwith pEX3. Themolecular
mass of this immunoreactive protein,30 kDa, is a similar size
to the tentative protein encoded by the second ORF in pEX3,
which codes for a putative lipoprotein. Thus, this putative
lipoproteinmay be an antigenicmolecule ofV. vulnificus found
in the immunoscreening assays.
Blast search of this putative lipoprotein reveals several
homologous proteins found in other pathogenic Gram-neg-
ative bacteria (Fig. 2). The deduced amino acid sequences of
thisV. vulnificus lipoprotein (GenBankTM accession number
DQ_177330) showed 84, 68, 53, and 59% identities to those
of Vibrio cholerae (GenBankTM accession number NP_230552),
Salmonella typhimurium (GenBankTM accession number NP_
459249), E. coli (GenBankTM accession number YP_859264),
and Haemophilus influenzae (GenBankTM accession number
P_317282), respectively. None of these proteins has yet been
reported with respect to their functional role. In all five pro-
teins, however, there is a conserved signal sequence and a cys-
teine residue, which have been known to be required for lipida-
tion (38). Therefore, we putatively designated this protein as
IlpA, which stands for immunogenic lipoprotein A.
Lipidation of the Recombinant IlpA Protein—The deduced
amino acid sequences of this putative protein contain a consen-
sus lipobox sequence for lipid modification at its N terminus,
which is Leu-Ala-Gly(Ala)-Cys (38). Using an expression sys-
tem of the rIlpA in E. coli, we investigated whether IlpA protein
is modified by lipidation as suggested from its amino acid
sequences (Fig. 3). The rIlpA protein was expressed in E. coli
BL21 (DE3) as a C terminus histidine-tagged form using the
pET28b-based expression plasmid, pETilpA, in which the
expression of the recombinant protein is induced by IPTG.
E. coliDH5was also used as a control strain, in which expres-
sion of the rIlpA was not induced by IPTG.
Four different E. coli strains, DH5 with pET28b, BL21
(DE3) with pET28b, DH5with pETilpA, and BL21 (DE3) with
pETilpA, were grown in the presence of [3H]palmitic acid and
examined for the presence of radiolabeled protein(s). Specifi-
cally, two of the four strains, DH5 carrying pETilpA and BL21
(DE3) carrying pETilpA, were cultured in the absence or pres-
ence of 1 mM IPTG and then compared side by side to examine
FIGURE2.Alignmentof thededuced lipoproteinaminoacid sequencesof
V. vulnificus, V. cholerae, E. coli, S. typhimurium, and H. influenzae. The
signal sequences for protein secretion and the positively charged lysine
within the N-terminal hydrophobic region, are indicated by open arrows, and
the cysteine residue for lipidation is denoted by a closed arrow. An asterisk
indicates a fully conserved residue. The two-dotted symbol indicates a
strongly similar residue, and the one-dotted symbol indicates a weakly similar
residue.
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whether the IPTG-induced protein might be labeled with
[3H]palmitic acid. Because proteinsmodified by lipidation have
detergent-soluble properties, lysates of each culture were sub-
divided into aqueous, detergent, and pellet fractions by their
solubility in Triton X-114.
A protein labeled with [3H]palmitic acid, the size of which is
30 kDa, was detected only in the lysates prepared from BL21
(DE3) with pETilpA, when grown in the presence of IPTG. This
result indicates that the rIlpA protein is lipidated as suggested
from its amino acid sequences. The lipid-containing property
of the rIlpA was also supported by observing the strongest
radioactivity in the detergent phase of IPTG-induced BL21
(DE3) bacteria with pETilpA.
Construction of ilpA Knock-out Mutant and Complementa-
tion of the Mutant—We constructed a mutant V. vulnificus, in
which its ilpA gene was deleted from the wild typeV. vulnificus
ATCC29307 to examine the functional role of this protein inV.
vulnificus. Two sets of primers were used to construct a knock-
out mutant, i.e. a set of two primers specific to the upstream
region (ilpA-upF and ilpA-upR) and a second set of primers
specific to the downstream region (ilpA-downF and ilpA-
downR) of the ilpA gene (Fig. 1A). The resultantmutant, YS101,
lacked a complete ORF of the ilpA gene. Deletion of the ilpA
gene in a chromosome of the mutant V. vulnificus was con-
firmed by PCR using primers ilpA-upF and ilpA-downR (Fig.
4A). The resultant PCRproduct of the ilpAmutantV. vulnificus
was 1,855 bp long, whereas wild type V. vulnificus with the
intact ilpA gene produced a larger PCR product of 2,665 bp.
The cellular level of the IlpA protein was also examined in wild
typeandilpAmutantV.vulnificusbyWesternblot analysisusing
polyclonal antibodies against rIlpA (Fig. 4B). A strong immuno-
reactive band of 30 kDa was detected only in the wild type
lysate. An intact ilpA gene of V. vulnificus was cloned into the
broad host range plasmid pLAFR5 to produce pLAFRilpA. The
ilpAmutantV. vulnificus carrying pLAFRilpA clearly demon-
strated a formation of the immunoreactive protein (Fig. 4B).
Cytokine Production of Human PBMCs Induced by Cell
Extracts of Various V. vulnificus Strains—Repeated isolation of
ilpA-containing clones from immunoscreening of V. vulnificus
expression library with anti-OMP serum led us to examine the
possibility that IlpA of V. vulnificus acts as an immunostimu-
lant to induce cytokine production in human cells. Thus, we
prepared a V. vulnificus lysate devoid of the IlpA protein using
FIGURE3.Autoradiographof the rIlpA labeledwith [3H]palmitic acid.Var-
ious E. coli strains (DH5 carrying pET28b, DH5 carrying pETilpA, BL21 (DE3)
carrying pET28b, and BL21 (DE3) carrying pETilpA) at mid-log phase were
labeled with [3H]palmitic acid. Bacterial lysates were then phase-partitioned
with5% (v/v) TritonX-114at 37 °C. For two strains,DH5 carryingpETilpAand
BL21 (DE3) harboringpETilpA, the expressionof the recombinant proteinwas
induced by adding 1 mM IPTG. An equal amount of each fraction was sub-
jected to SDS-PAGE and transferred to a polyvinylidene difluoride mem-
brane. The membrane was treated with Amplify solution (Amersham Bio-
sciences) and exposed to x-ray film for 2 weeks. A, aqueous phase; D,
detergent phase; P, pellet. The 3H-labeled rIlpA is indicated by an arrow.
FIGURE 4. Confirmation of ilpA mutant strain (YS101) and its comple-
mentedstrainofV. vulnificus.A,deletionof the ilpA locus in the strainYS101
was confirmedbyPCRusinga setofprimers, ilpA-upFand ilpA-downR (Fig. 1).
Lane 1, DNA size marker (HindIII-digested  phage DNA); lane 2, PCR product
of wild type ATCC29307; lane 3, PCR product of YS101; and lane 4, DNA size
marker (100 bp ladder). B, Western blot of various V. vulnificus strains using
polyclonal antibodies specific to rIlpA. Each lane contains 20 g of bacterial
lysate prepared fromwild type ATCC29307 (lane 1), theilpAmutant (lane 2),
or theilpAmutant complementedwith the intact ilpA gene in pLAFR5 (lane
3). An immunoreactive band of30 kDa is indicated by an arrow.
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the ilpA mutant YS101 and compared its activity to induce
cytokine production with that of wild type V. vulnificus. When
human PBMCs were treated with various concentrations of
wild type lysate (ranged from 0.5–10.0 g/ml), the secretion of
IFN- by PBMCswas increased up to 1,310 pg/ml in a dose-de-
pendent manner (Fig. 5). In contrast, treatment of PBMCs with
the lysate of the ilpA mutant V. vulnificus produced a much
lower level of IFN- (41 pg/ml), which was a comparable value
to those of the control cells, such as PBMCs treated with
medium only or bovine serum albumin (13 or 32 pg/ml,
respectively).
When lysate of the ilpA mutant V. vulnificus carrying
pLAFRilpA was used to challenge PBMCs, IFN- production
was restored to the levels induced by the equivalent concentra-
tions of wild type V. vulnificus lysate. This result suggests that
V. vulnificus IlpA protein stimulates an immune response in
human cells.
Cytokine ProductionofHumanPBMCsandMonocytes Induced
by rIlpAProtein—Based on the drastic difference in immunogeni-
cally stimulating activity between lysates of wild type and ilpA
mutantV. vulnificus, we asked whether the IlpA protein itself was
able to induce production of IFN- in PBMCs (Fig. 6A). Indeed,
when rIlpA protein was added at a concentration of 1.0 g/ml to
PBMCs, IFN-was increased to 1,080 pg/ml. This was equivalent
to the IFN- level in a positive control (1,320 pg/ml), in which
PBMCswere treatedwith1.0g/ml concanavalinA, awell known
molecule to induce production of IFN- (39).
In subsequent experiments, we examined the ability of rIlpA
to induce the production of cytokines in monocytes. Mono-
cytes prepared from human PBMCs were challenged with var-
ious concentrations of rIlpA (0.01–1.0 g/ml) and assayed for
production of TNF- (Fig. 6B) and IL-6 (Fig. 6C). As a positive
control, E. coli LPS was used to stimulate cytokine production
by monocytes. When these rIlpA-treated monocytes were
assayed for cytokine production at 18 h post-stimulation,
increasing amounts of both cytokines were detected in a dose-
dependent manner of rIlpA (up to 14,500 pg/ml for TNF- and
FIGURE 5. Cytokine production of human PBMCs induced by V. vulnificus
cell lysates. PBMCs were isolated by centrifugation of heparinized human
blood over a Ficoll-Paque density gradient at 1,600 rpm for 30 min. PBMCs
(1105)were then incubatedwith various concentrationsofbacterial lysates
up to 10.0g/ml for 18h. The concentrations of IFN- stimulatedby lysates of
wild type, ilpAmutant, and complemented ilpAmutant V. vulnificus were
determined using human IFN- ELISA kit (BD Biosciences) and indicated as
closed circles, open circles, and closed inverted triangles, respectively. Error bars
represent the standard deviations from three independent experiments.
IFN- production induced by each lysate of V. vulnificus was measured in
triplicate for each experiment.
FIGURE 6. Cytokine production induced by rIlpA of V. vulnificus. A, pre-
pared PBMCs (1 105) were incubated with 1.0g/ml rIlpA for 18 h, and the
supernatant of each culturewas used to determine the level of IFN- produc-
tion using a human IFN- ELISA kit (BD Biosciences). PBMCs exposed to con-
canavalin A (con A) (1.0 g/ml) were included as a positive control for IFN-
production. In addition, PBMCs were also treated with medium or bovine
serum albumin and assayed for cytokine production as negative controls.
BandC, confluentmonocytes (1105/ml),whichwerepreparedasdescribed
under “Experimental Procedures,” were exposed to various concentrations of
rIlpA protein ranging from 0.01 to 1.0 g/ml. Monocytes treated with E. coli
LPSwereused as apositive control for cytokineproduction. Cytokine concen-
trations were measured using a human TNF- ELISA kit (BIOSOURCE) and a
human IL-6 ELISA kit (BIOSOURCE). Error bars represent the standard devia-
tions from three independent experiments. Measurement of each cytokine
induced by rIlpA was performed in triplicate for each experiment.
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10,200 pg/ml for IL-6). In response to the increased amount of
LPS, monocytes displayed increased formation of these two
cytokines, up to 8,050 pg/ml for TNF- and 7,220 pg/ml for
IL-6. These results indicate that rIlpA of V. vulnificus is as
potent as E. coli LPS in inducing cytokine production by
monocytes.
Treatment of rIlpA Protein with Polymyxin B—LPS of Gram-
negative bacteria is known as a potent immunostimulant (40),
and the rIlpA protein used in this experiment was prepared
from the Gram-negative bacterial cell, E. coli BL21 (DE3). Thus
we examined the possibility that cytokine production by rIlpA-
stimulated monocytes was caused from the residual contami-
nation of LPS in the purified fraction of rIlpA. To exclude this
possibility, polymyxin B, an amphipathic LPS-binding mole-
cule, was used to antagonize the function of LPS. The poly-
myxin B-treated rIlpA was used to stimulate monocytes, upon
which the production of TNF- (Fig. 7A) and IL-6 (Fig. 7B) was
determined. As a positive control to confirm the proper func-
tioning of polymyxinB, LPSwas also pretreatedwith polymyxin
B before it was used for monocyte activation. As expected, the
ability of polymyxin B-treated LPS to stimulate cytokine pro-
duction in monocytes was dramatically attenuated compared
with the ability of untreatedLPS-stimulatedmonocytes. In con-
trast, preincubation of rIlpAwith polymyxinBdid not affect the
ability of rIlpA to induce cytokine production in monocytes.
This result clearly demonstrates that the rIlpA protein used in
this experiment was free of LPS contamination, and the cyto-
kine production by rIlpA-exposed monocytes is derived from
immunogenic activity of IlpA of V. vulnificus.
Role of Lipid Moiety of IlpA in Cytokine Production in
Monocytes—The amino acid sequence of IlpA has a putative
sequence for lipid modification, and lipidation of rIlpA was
confirmed by in vivo labeling assay (Fig. 3). In the case of the
Borrelia burgdorferi surface lipoprotein, its lipid moiety has
been reported to be crucial for immunogenic function (41). To
examine the role of the IlpA lipidmoiety in cytokine production
by monocytes, we synthesized a truncated rIlpA protein, in
which 23 N-terminal residues were deleted. Because the miss-
ing region of the mutant rIlpA protein contains important
amino acid residues required for lipidation, this proteinwas not
expected to be modified by lipidation, as shown previously in
other lipoproteins (41). Monocytes were stimulated with the
mutant rIlpA at a various concentrations from 0.001 to 1.0
g/ml, and then assayed for production of TNF- (Fig. 8A) and
FIGURE 7. Effect of polymyxin B on cytokine production by rIlpA-treated
monocytes. Polymyxin B was added to rIlpA at a concentration of 20 g/ml
to neutralize residual LPS, which might be coeluted during the purification
process for rIlpA. Monocytes (5 105) were seeded in 24-well culture plates
and exposed to rIlpA protein or to polymyxin B-treated rIlpA at a concentra-
tion of 1.0 g/ml. LPS of E. coli was also treated simultaneously with poly-
myxin B to provide a control for the neutralizing effect of polymyxin B against
LPS. Following an 18-h exposure to the rIlpAprotein or LPS, the culture super-
natants were collected and then assayed for TNF- (A) or IL-6 (B) by ELISA as
described under “Experimental Procedures.” Error bars represent the stand-
ard deviations from three independent experiments. Induction of each cyto-
kine by IlpA, polymyxin B-treated rIlpA, LPS, or polymyxin B-treated LPS was
performed in triplicate for each experiment.
FIGURE 8. Role of the lipid moiety of rIlpA in cytokine production by
monocytes. Confluentmonocytic cells (1 105/ml) were exposed for 18 h to
various concentrations of the wild type rIlpA protein or nonlipidatedmutant
rIlpAprotein (rmIlpA) ranging from0.01 to1.0g/ml. LPSof E. coliwasusedas
a positive control for induction of cytokine production inmonocytes. Culture
supernatants were then collected and assayed for TNF- (A) and IL-6 (B) by
ELISA as described under “Experimental Procedures.” Error bars represent the
standard deviations from three independent experiments. Production of
each cytokine by wild type rIlpA or rmIlpA at various concentrations was
measured in triplicate for each experiment.
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IL-6 (Fig. 8B). As a control, another set of monocytes was
treated with intact IlpA at the same concentrations as the
mutant IlpA, and then assayed for cytokine production. When
monocytes were treated with the mutant rIlpA at low concen-
trations (less than 0.1g/ml), only basal levels of cytokineswere
detected. Formation of significant amounts of cytokines was
observed in monocytes stimulated with relatively high concen-
trations of the mutant rIlpA (0.1 and 1.0 g/ml). On the other
hand, considerable amounts of both TNF- and IL-6 were
formed in monocytes challenged with even the lowest concen-
tration (0.001 g/ml) of the intact IlpA, and cytokine produc-
tion increased in proportion with IlpA concentration as shown
in Fig. 6. Monocytes exposed to 0.1 g/ml LPS were also exam-
ined for their induction of TNF- and IL-6 production tomon-
itor the proper experimental procedures, such as a stimulus
treatment and cytokine assays. This result indicates that the
nonlipidatedmutant rIlpAwas significantly impaired in its abil-
ity to induce cytokine production inmonocytes compared with
the ability of intact lipidated IlpA.
Role of TLR2 in Cytokine Production by IlpA-stimulated
Monocytes—In this experiment, we investigated how the IlpA
protein ofV. vulnificuswas recognized by humanmonocytes to
result in cytokine production. In particular, we examined
whether IlpA-induced cytokine production is mediated by a
TLR family member, e.g. well known receptors for pathogen-
associated molecular patterns, which relay information with
respect to microbial components resulting in innate immunity.
In Mycobacterium tuberculosis, antigenic lipoproteins were
reported to be recognized by TLR2 (42). In addition, TLR2,
which has been reported to function in inflammatory events
associated with Lyme arthritis, recognizes lipoproteins of B.
burgdorferi (43). Thus, we examined whether the IlpA of V.
vulnificus also activates human monocytes via its interaction
with TLR2.
To examine the possibility that TLR2 is involved in IlpA-
induced cytokine production of monocytes, monocytes were
pretreatedwith antibodies specific to TLR2 prior to being stim-
ulated with rIlpA. As a control, another set of monocytes was
pretreatedwith isotype control IgG instead of TLR2 antibodies,
and then stimulated with rIlpA by the identical manner. These
rIlpA-challenged monocytes were then assayed for production
of TNF- (Fig. 9A) and IL-6 (Fig. 9B). As shown in the previous
figures, both TNF- and IL-6 were produced in monocytes
challengedwith rIlpA. Pretreatment ofmonocytes with the IgG
control did not affect the formation of these two cytokines by
rIlpA. In contrast, cells pretreated with TLR2 antibodies
showed significant decrease in both TNF- and IL-6 produc-
tion compared with isotype IgG-treated monocytes (p  0.02,
Student’s t test).
LPS is known to be recognized by another TLR, TLR4 (26,
44). Thus, another set of monocytes was challenged with LPS
FIGURE 9.Role of TLR2 in cytokineproductionby rIlpA-stimulatedmono-
cytes. A and B, human monocytes were preincubated for 1 h with either
anti-TLR2 antibodies or with the relevant isotype IgG control. These cells
were then stimulated with rIlpA (1.0 g/ml) for 18 h, and then culture
supernatants were assayed for TNF- (A) and IL-6 (B) by ELISA as described
under “Experimental Procedures.” A control set of monocytes pretreated
with either the TLR2 antibodies or with the control IgG was stimulated
with LPS instead of rIlpA and then assayed for cytokine production. C, HEK
293 cells (5  105), which have been transfected with pFLAG-TLR2,
p(IL6B)350hu.IL6P-luc, and pCH110, were stimulated with rIlpA (1.0
g/ml), incubated for an additional 20 h, and lysed to determine both
luciferase and -galactosidase activities. The NF-B activities were shown
by dividing the luciferase activities (relative light units) by the -galacto-
sidase activities of the identical sample. As controls, plasmid pFLAG-CMV
or pFLAG-TLR4 was included in the transfection experiments. Error bars
represent the standard deviations from three independent experiments.
Production of IL-6 or TNF- was measured in triplicate for each sample.
Asterisks indicate cytokine levels that were significantly different from that
of untreated monocytes by the Student’s t test. Data with a p value of
0.01 are indicatedwith **, and data with a p value between 0.01 and 0.05
are represented with *.
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instead of rIlpA to determine whether the neutralizing activity
of anti-TLR2 antibodies occurred only in rIlpA-treated cells but
not in LPS-treated cells. Both the isotype IgG and anti-TLR2
antibodies were ineffective in inhibiting cytokine production in
LPS-stimulated monocytes. This result suggests that the IlpA
protein of V. vulnificus may act as an immunostimulant to
monocytes by being recognized via TLR2.
To investigate the function of TLR2 in IlpA-induced cyto-
kine production in humanmonocytes, we also reconstituted an
in vitro system using HEK 293 cells, in which either TLR2 or
TLR4 was expressed along with their common adaptor protein
MyD88 (45). As a control, another set of HEK 293 cells was
transfected with pFLAG-CMV1, the empty vector for pFLAG-
TLR2 (a TLR2-expressing plasmid; see Ref. 35) or pFLAG-
TLR4 (a TLR4-expressing plasmid; see Ref. 35). To monitor
cytokine production using a reporter gene, this system includes
a luciferase reporter for NF-B activities, p(IL6B)350hu.IL6P-
luc (36). For each transfection, the lacZ-plasmid pCH110
was included to normalize luciferase activities by dividing with
the -galactosidase activities of the same transfectant.
The ability of rIlpA to induce cytokine production was mon-
itored by determining luciferase activities of the TLR2-express-
ing HEK 293 cells, the TLR4-expressing HEK 293 cells, and the
control HEK 293 cells (Fig. 9C). In the absence of rIlpA, all of
theHEK293 cells showed basal levels of the luciferase activities.
Upon stimulation with rIlpA, all three HEK 293 cells showed
increased luciferase activities. Interestingly, the HEK 293 cells
transfected with pFLAG-TLR2 demonstrated the most dra-
matic increase in their NF-B activities. On the contrary, the
increase in luciferase activity was significantly less in the TLR4-
expressing cells and the control HEK 293 cells than the TLR2-
expressing HEK 293 cells.
Induction of TLR2 Transcription in Human PBMC and 293-
hTLR Cell Lines by IlpA Treatment—To determine whether
TLRs are expressed in the response to IlpA protein of V. vulni-
ficus, we examined the levels of TLR2 and TLR4 mRNAs in the
IlpA-treated cells by RT-PCR.When humanPBMCswere chal-
lenged with rIlpA (1.0 g/ml) for 1 h, the level of TLR2 mRNA
was significantly increased (Fig. 10A). On the other hand, LPS-
treated PBMC demonstrated increased levels of TLR4 mRNA
at 5 h of post-stimulation (Fig. 10A). IlpA did not affect the level
of TLR4mRNA, and LPS did not influence the TLR2mRNA in
PBMC.
Two 293-hTLRs cell lines expressing either TLR2 or TLR4
were also examined for their response to IlpA by RT-PCR (Fig.
10B). Expression of TLR2 was increased in 293-hTLR2 cells at
1 h of exposure to rIlpA, whereas it was not affected by LPS
stimulation at all. The amount of TLR4 mRNA was dramati-
cally increased at 5 h after LPS stimulation in 293-hTLR4 cells.
On the other hand, the level of TLR4 mRNA was only slightly
increased by rIlpA treatment at 5 h in the 293-hTLR4 cells. The
levels of GAPDH mRNA were examined as the controls for
RNA amount.
Role of IlpA in Lethality of V. vulnificus to Mice—We exam-
ined the role of the IlpA protein in pathogenesis ofV. vulnificus
by using a mouse infection model. Upon intraperitoneal injec-
tion of various numbers of bacterial cells into mice, the num-
bers of dead mice were determined at 24 h after the injection
(Table 2). One of two experiments was presented as a repre-
sentative experiment. Mice infected with the wild type showed
an LD50 of 9.5 104 cells, whereasmice injectedwith theilpA
mutant showed an 8-fold higher LD50 (7.5 105 cells).
DISCUSSION
Human innate immune system recognizes microbial patho-
gens via action of its highly conserved pattern recognition
receptors for microbial molecules, including LPS, peptidogly-
FIGURE 10. Induction of Toll-like receptor mRNAs in human PBMCs, 293-
hTLR2, and 293-hTLR4 cells. A, total RNA was prepared from PBMCs (2 
106) incubated with 1.0 g/ml rIlpA for 1 h or with 1.0 g/ml LPS for 5 h, and
analyzed for their transcript levels of GAPDH, TLR2, and TLR4 using RT-PCR as
describedunder “Experimental Procedures.” B, levels of TLR2mRNAand TLR4
mRNA were monitored by RT-PCR in 293-hTLR2 and 293-hTLR4 cells, which
were pretreated with rIlpA or E. coli LPS. cDNA from a single RT reaction
(derived from either 293-hTLR2 or 293-hTLR4) was used as a template for
individual PCR with TLR2-specific primers or with TLR4 specific primers,
respectively. Specific amplicons were visualized by 1.8% agarose gel electro-
phoresis and staining with ethidium bromide. GAPDHmRNA encoding glyc-
eraldehyde-3-phosphate dehydrogenase was served as a loading control for
RNA amount.
TABLE 2
Lethality of V. vulnificus strains to mice
Strain Genotype
No. of dead mice/no. of total mice
for no. of injected bacteria LD50
3.0 103 3.0 104 3.0 105 3.0 106
CFU
ATCC29307 Wildtype 0:6 1:6 5:6 6:6 9.5 104
YS101 ilpA 0:6 0:6 1:6 6:6 7.5 105
a CFU indicates colony-forming units.
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cans, lipoteichoic acids, and lipoprotein. Lipoproteins are pro-
duced by both Gram-negative and Gram-positive bacteria, and
some lipoproteins are known as the abundant proteins in cer-
tain Gram-negative bacteria (19).
Lipoproteins of several microorganisms are known to acti-
vate a variety of host cells to produce cytokines. InMycoplasma
lacking a cell wall, surface lipoproteins such as VlpA and VlpC
have been reported to induce cytokine production in macro-
phages (46). Several lipoproteins, LpqH, LpqG, and LprA,
have been documented in M. tuberculosis to trigger innate
inflammation (43, 47, 48). In addition, the signaling pathway
involved in lipoprotein-induced activation of immune cells
was found to be distinct from that involved by the LPS-in-
duced process (49).
In this study, a lipoprotein of V. vulnificuswas identified as a
surface protein showing a potent antigenic property (Fig. 1).
Therefore, we examined if this protein was able to stimulate the
human cells to produce cytokine. Because the intact V. vulnifi-
cus exhibits too strong a cytotoxicity toward various types of
human cells,3 it is not applicable to measure cytokine produc-
tion by directly treating PBMCs with intact V. vulnificus. Thus,
bacterial lysates or recombinant proteins were used in this
study. Indeed, wild type V. vulnificus lysate was effective to
trigger cytokine production by human PBMCs, but V. vulnifi-
cus lysate lacking the isolated lipoprotein was significantly
defective in cytokine induction (Fig. 5). Based on an observation
that this lipoprotein ofV. vulnificus functions as amajor immu-
nostimulant, we designated this protein as IlpA, which stands
for immunogenic lipoprotein A. This is the first report on a
lipoprotein of Vibrio spp. with immunostimulating activity.
The lipoprotein from other Gram-negative bacteria, such asN.
gonorrhoeae andLegionella pneumophila (50, 51), have the abil-
ity to stimulate the production of proinflammatory mediators
in mammalian cells.
TLRs, a group of well known receptors of the innate immune
response, contain a cytoplasmic domain, which is homologous
to the signaling domain of the IL-1 receptor. Each TLR senses
the presence of the specific components of pathogens and
transfers the information to a signaling pathway leading to the
activation of NF-B. Activation of NF-B results in the tran-
scription of genes coding for various cytokines (24). In the case
of lipoproteins, TLR2has been found as amain cellular receptor
in several pathogenic bacteria. For example, a 19-kDa lipopro-
tein ofMycobacterium has been shown to trigger the signaling
pathway of the host cells primarily through TLR-2, resulting in
a production of IL-12/NO by monocytes/macrophages and an
apoptosis of monocytes (42, 52). In the case of V. vulnificus
IlpA, it activates monocytes to produce TNF- and IL-6 in a
similar manner as LPS (Fig. 6). The receptor for Gram-negative
bacterial LPS has been shown to be TLR4 (26). Therefore, the
receptor for IlpA on monocytes was examined using two inde-
pendent assays that clearly demonstrated the involvement of
TLR2 in IlpA-mediated cytokine induction in monocytes.
Cytokine production in rIlpA-stimulatedmonocytes is blocked
by pretreatment with antibodies specific to human TLR2 (Fig.
9,A andB). In addition,V. vulnificus rIlpA induced activation of
NF-B only in the HEK 293 cell line expressing TLR2 (Fig. 9C),
whereas it did not induce NF-B activation in HEK 293 cells
expressing TLR4.
Lipoproteins are presentmainly in two forms, diacylated or
triacylated (53). At present, biochemical properties of
lipoproteins were extensively studied in Mycoplasma spp.
(54). Mycoplasma gallisepticum and Mycoplasma mycoides
have both diacylated and triacylated forms of lipoproteins
(53). In TLR1-deficient mice, the macrophage-activating
lipopeptide from Mycoplasma fermentans (MALP-2) con-
taining two acyl chains failed to induce cytokine production,
whereas N-palmitoyl-(S)-[2,3-bis(palmitoyloxy)-(2R,2S)-pro-
pyl] (Pam3)/Cys-Ser-Lys-4 (CSK4) (Pam3CSK4) containing
three acyl chains induced cytokine formation (55), suggest-
ing that only triacylated lipoproteins are recognized by the
combined action of TLR1 and TLR2. In vivo research using
TLR6-knock-out mice indicates that diacylated lipoproteins
are recognized by TLR6 in conjunction with TLR2 (56). Our
data indicated that TLR2 is the main receptor responsible for
V. vulnificus IlpA-mediated immune response. However, a
role for other TLRs in this process is not yet known, and thus
future investigation will be performed to unveil the bio-
chemical characteristics of IlpA, and the roles of TLR1 and
TLR6 in V. vulnificus IlpA-induced activation of human
monocytes.
In many known lipoproteins having immunological activity,
the portions of the proteins responsible for their immunologi-
cal activity are located at theN-terminal triacylated lipopeptide
region (42, 57, 58). The importance of lipidation inV. vulnificus
IlpA was also confirmed by an observation that cytokine pro-
duction in human monocytes triggered by nonlipidated rIlpA
was significantly less than that by the intact lipidated rIlpA (Fig.
8). However, the nonlipidated form of V. vulnificus IlpA still
retains an ability to induce cytokine production inmonocytes at
high concentrations. This finding raises the possibility that
some domain(s) of V. vulnificus IlpA protein portion functions
as a minor immunostimulant.
One of the distinct pathologies in V. vulnificus-causing
septicemia is the clinical progression of the systemic inflam-
matory response (18). The potent immunostimulating activ-
ity of IlpA we observed suggests that this microbial factor
may be responsible for the progressive pathogenesis of V.
vulnificus. The importance of surface lipoprotein in systemic
inflammation has been already reported in spirochaetal
microorganisms lacking LPS (59). Increased levels of proin-
flammatory cytokines, such as TNF-, IL-1, and IL-6, in the
serum from V. vulnificus-infected patients have been
reported (60), which supports the speculated role for dys-
regulation of the cytokine response for the pathogenesis of
V. vulnificus. Here we also provide evidence supporting the
above clinical observation by showing an increased produc-
tion of the proinflammatory cytokines, TNF- and IL-6, in
monocytes upon exposure to IlpA of V. vulnificus. Thus, V.
vulnificus IlpA protein, which is capable of activating mono-
cytes to produce cytokines, would be a potential molecule in
the development of prevention and a therapy agent for V.
vulnificus infection.3 W. H. Kim and S.-J. Park, unpublished data.
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